-
1Academic Journal
Συγγραφείς: A. V. Polynovskiy, Z. Z. Mamedli, D. V. Kuzmichev, A. A. Tryakin, O. A. Kuznetsova, S. O. Kochkina, A. A. Aniskin, A. S. Gorbunova, D. V. Aleksancev, H. R. Temirsultanova, А. В. Полыновский, З. З. Мамедли, Д. В. Кузьмичев, А. А. Трякин, О. А. Кузнецова, С. О. Кочкина, А. А. Анискин, А. С. Горбунова, Д. В. Алексанцев, Х. Р. Темирсултанова
Συνεισφορές: The article was prepared without sponsorship, Статья подготовлена без спонсорской поддержки
Πηγή: Malignant tumours; Том 14, № 2 (2024); 65-74 ; Злокачественные опухоли; Том 14, № 2 (2024); 65-74 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: химиолучевая терапия, total neoadjuvant therapy, chemoradiotherapy, тотальная неоадъювантная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1328/945; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.250 с.; The Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 2013;100(8):1009–1014. doi:10.1002/bjs.9192; Zwart W.H., Hotca A., Hospers G.A.P., et al. The multimodal management of locally advanced rectal cancer: making sense of the new data. Am Soc Clin Oncol Educ Book 2022;42:1–14. doi:10.1200/EDBK_351411; Mendis S., Hang To Y., Tie J. Biomarkers in locally advanced rectal cancer : a review. Clin Colorectal Cancer 2022;21(1):36–44. doi:10.1016/j.clcc.2021.11.002; Van Gijn W., Marijnen C.A.M., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–582. doi:10.1016/S1470-2045(11)70097-3; Erlandsson J., Holm T., Pettersson D., et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18(3):336–346. doi:10.1016/S1470-2045(17)30086-4; Cionini L., Sainato A., De Paoli A., et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96: S113-S114.; Breugom A.J., Swets M., Bosset J.F., et al. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer : a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16(2):200–207. doi:10.1016/S1470-2045(14)71199-4; Morris M.C., Winer L.K., Lee T.C., et al. Omission of adjuvant chemotherapy in rectal cancer patients with pathologic complete response: a national analysis. J Gastrointest Surg 2021;25(7):1857–1865. doi:10.1007/s11605-020-04749-6; Bahadoer R.R., Dijkstra E.A., Van Etten B., et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2020;22(1):29–42. doi:10.1016/S1470-2045(20)30555-6; Conroy T., Bosset J.-F., Etienne P-L., et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial; Lancet Oncol 2021;22(5):702–715. doi: /10.1016/S1470-2045(21)00079-6; Jin J., Tang Y., Hu C., et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022;40(15):1681–1692. doi:10.1200/JCO.21.01667; Liao C.-K., Kuo Y.-T., Lin Y.-C. et. al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer : a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–3727. doi:10.3390/curroncol29050297; Sauer R., Liersch T., Merkel S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30(16):1926–1933. doi:10.1200/JCO.2011.40.1836; Gao Y.-H., Lin J.-Z., An X., et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 2014;90(5):1153–1160. doi:10.1016/j.ijrobp.2014.07.021; Fernandez-Martos C., Garcia-Albeniz X., Pericay C., et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26(8):1722–1728. doi:10.1093/annonc/mdv223; Bujko K., Wyrwicz L., Rutkowski A., et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016;27(5):834–842. doi:10.1093/annonc/mdw062; Fokas E., Allgäuer M., Polat B., et al. Randomized phase ii trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37(34):3212–3222. doi:10.1200/JCO.19.00308.; Dijkstra E.A., Nilsson P.J., Hospers G.A.P., et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery. A 5-year follow-up of the RAPIDO trial. Ann Surg 2023;278(4):e766-e772. doi:10.1097/SLA.0000000000005799; Romesser P.B., Park B.K., Nemirovsky D., et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy. Meeting Abstract 2023 ASCO Annual Meeting I GASTROINTESTINAL CANCER—COLORECTAL AND ANAL. doi:10.1200/JCO.2023.41.4_suppl.10; Garcia-Aguilar J., Patil S., Gollub M.J., et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022:40(23):2546–2556. doi:10.1200/JCO.22.00032; Petrelli F., Trevisan F., Cabiddu M., et al. Total neoadjuvant therapy in rectal cancer : a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020;271(3):440–448. doi:10.1097/SLA.0000000000003471; Liu S., Jiang T., Xiao L., et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer : a systematic review and meta-analysis. Oncologist 2021;26(9):e1555-e1566. doi:10.1002/onco.13824; Kong J.C., Soucisse M., Michael M., et al. Total neoadjuvant therapy in locally advanced rectal cancer : a systematic review and metaanalysis of oncological and operative outcomes. Ann Surg Oncol 2021;28(12):7476–7486. doi:10.1245/s10434-021-09837-8; Wu Q., Zhou J., Huang J., et al. Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: Bayesian network meta-analysis. Br J Surg 2023;110(7):784–796. doi:10.1093/bjs/znad120; Habr-Gama A., Perez R.O., Nadalin W., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–717. doi:10.1097/01.sla.0000141194.27992.32; Garcia-Aguilar J., Chow O.S., Smith D.D., et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015;16(8):957–966. doi:10.1016/S1470-2045(15)00004-2; Markovina S., Youssef F., Roy A., et al. Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biol Phys 2017;99(2):417–426. doi:10.1016/j.ijrobp.2017.05.048; Glynne-Jones R., Counsell N., Quirke P., et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014;25(7):1356–62. doi:10.1093/annonc/mdu147; Breugom A.J., van Gijn W., Muller E.W., et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015;26(4):696–701. doi:10.1093/annonc/mdu560; Hong Y.S., Kim S.Y., Lee J.S., et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol 2019;37(33):3111–3123. doi:10.1200/JCO.19.00016; Dijkstra E.A., Hospers G.A., Kranenbarg E.M.-K., et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer–The RAPIDO trial. Radiother Oncol 2022;171:69–76. doi:10.1016/j.radonc.2022.04.013.; https://www.malignanttumors.org/jour/article/view/1328
-
2Academic Journal
Συγγραφείς: S. S. Gordeev, M. Yu. Fedyanin, M. V. Chernykh, Ye. G. Rubakov, A. M. Karachun, A. A. Nevolskikh, A. A. Tryakin, Z. Z. Mamedli, С. С. Гордеев, М. Ю. Федянин, М. В. Черных, Е. Г. Рыбаков, А. М. Карачун, А. А. Невольских, А. А. Трякин, З. З. Мамедли
Πηγή: Surgery and Oncology; Том 14, № 1 (2024); 21-31 ; Хирургия и онкология; Том 14, № 1 (2024); 21-31 ; 2949-5857
Θεματικοί όροι: тотальная неоадъювантная терапия, colon cancer, colorectal cancer, clinical guidelines, neoadjuvant chemotherapy, total neoadjuvant therapy, рак ободочной кишки, колоректальный рак, клинические рекомендации, неоадъювантная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/687/451; Sakamoto T., Shimura M., Kitano S. et al. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132–9. DOI:10.1148/radiol.2431051825; Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd et al. Rectal cancer. J Natl Compr Canc Netw 2009:7(8):838–81. DOI:10.6004/jnccn.2009.0057; De Caluwé L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013(2):CD006041. DOI:10.1002/14651858.CD006041.pub3; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Dijkstra E.A., Nilsson P.J., Hospers G.A.P. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery–a five-year follow-up of the RAPIDO trial. Ann Surg 2023;278(4):e766–72. DOI:10.1097/SLA.0000000000005799; Song J.H., Jeong J.U., Lee J.H. et al. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J 2017;35(3): 198–207. DOI:10.3857/roj.2017.00059; Battersby N.J., How P., Moran B. et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016;263(4):751–60. DOI:10.1097/SLA.0000000000001193; Marinello F.G., Frasson M., Baguena G. et al. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. Dis Colon Rectum 2015;58(6):556–65. DOI:10.1097/DCR.0000000000000349; Rosenberg R., Maak M., Schuster T. et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum 2010;53(5):761–70. DOI:10.1007/DCR.0b013e3181cdb25a; Folkesson J., Birgisson H., Pahlman L. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23(24):5644–50. DOI:10.1200/JCO.2005.08.144; Sebag-Montefiore D., Stephens R.J., Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811–20. DOI:10.1016/S0140-6736(09)60484-0; Van Gijn W., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575–82. DOI:10.1016/S1470-2045(11)70097-3; Morton D., Seymour M., Magill L. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023;41(8):1541. DOI:10.1200/JCO.22.00046; Hu H., Huang M., Li Y. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.3500; Jensen L.H., Kjaer M.L., Holländer N.H., Larsen F.O. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol 2023;41(17_suppl):LBA3503. DOI:10.1200/JCO.2023.41.17_suppl.LBA3503; Karoui M., Rullier A., Piessen G. et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg 2020;271(4):637–45. DOI:10.1097/SLA.0000000000003454; Ngan S.Y., Burmeister B., Fisher R.J. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827–33. DOI:10.1200/JCO.2012.42.9597; Cisel B., Pietrzak L., Michalski W. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019;30(8):1298–303. DOI:10.1093/annonc/mdz186; Dijkstra E.A., Hospers G.A.P., Kranenbarg E.M. et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiother Oncol 2022;171:69–76. DOI:10.1016/j.radonc.2022.04.013; Birgisson H., Påhlman L., Gunnarsson U., Glimelius B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol 2007;46(4):504–16. DOI:10.1080/02841860701348670; Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177–88. DOI:10.1056/NEJMoa1713709; Schrag D. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)(Alliance N1048). American Society of Clinical Oncology 2023.; Mei W.-J., Wang X.Z., Li Y.F. et al. Neoadjuvant chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023;277(4):557–64. DOI:10.1097/SLA.0000000000005780; Hazen S.-M.J., Sluckin T.C., Intven M.P.W. et al. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes. JAMA Oncol 2024;10(2):202–11. DOI:10.1001/jamaoncol.2023.5444; Sychev S., Ponomarenko A., Chernyshov S. et al. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol 2023;39(4):289–300. DOI:10.3393/ac.2022.00920.0131; Verheij F.S., Omer D.M., Williams H. et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol 2023:42(5):500–6. DOI:10.1200/JCO.23.01208; Liao C.-K., Kuo Y.T., Lin Y.C. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Verheij F.S., Omer D.M.R., Williams H. et al. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.352; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4_suppl). DOI:10.1200/JCO.2023.41.4_suppl.10; Van der Valk M.J., Hilling D.E., Bastiaannet E. et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018;391(10139):2537–45. DOI:10.1016/S0140-6736(18)31078-X; Ellis C.T., Cole A.L., Sanoff H.K. et al. Evaluating surveillance patterns after Chemoradiation-only compared with conventional Management for Older Patients with rectal cancer. J Am Coll Surg 2019;228(5):782–91. DOI:10.1016/j.jamcollsurg.2019.01.010; Giordano P., Efron J., Vernava A.M. 3rd et al. Strategies of followup for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech Coloproctol 2006;10(3):199–207. DOI:10.1007/s10151-006-0280-3; Федянин М., Гладков О., Гордеев С. и др. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2-1):425–82. DOI:10.18027/2224-5057-2023-13-3s2-1-425-482; Федянин М., Трякин А.А., Буланов А.А. и др. К вопросу о числе лимфатических узлов, необходимых к изучению при раке толстой кишки II стадии. Тазовая хирургия и онкология 2019;9(1):42–50. DOI:10.17650/2220-3478-2019-9-1-42-50; Jeon J., Shen L., Kim Y. et al. The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3612; Ahmed F., Selfridge J., Kakishet H. et al. SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis. Ann Oncol 2023;34(1_suppl):S170. DOI:10.1016/j.annonc.2023.04.491; Fleming P., Chen Ch., Moore D.F. et al. High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.e15588; Oki E., Kotani D., Nakamura Y. et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3521; Tie J., Cohen J.D., Lahouel K. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261–72. DOI:10.1056/NEJMoa2200075; Cohen S.A., Kasi P.M., Aushev V.N., Hanna D. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I–III colorectal cancer. J Clin Oncol 2023;41(4_suppl):5. DOI:10.1200/JCO.2023.41.4_suppl.5; Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI:10.1111/codi.15585